RT Journal Article
T1 IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
A1 Leyva-Fernández, Laura
A1 Fernández-Fernández, Óscar
A1 Fedetz, María
A1 Blanco, Eva
A1 Fernández, Victoria E.
A1 Oliver-Martos, Begoña
A1 León, Antonio
A1 Pinto-Medel, María Jesús
A1 Mayorga Mayorga, Cristobalina
A1 Guerrero, Miguel
A1 Luque, Gloria
A1 Alcina, Antonio
A1 Matesanz, Fuencisla
K1 Esclerosis múltiple - Tratamiento
K1 Polimorfismo genético
K1 Neuroinmunología
AB We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNβ treatment response in a group of 147 patients and 210 controls undergoing interferon therapy during the last 2 years. Only the 18417 and the 11876 SNPs showed an association with disease susceptibility (p = 0.001 and 0.035, respectively) although no differential genotype distribution were observed between interferon responders and non-responder MS patients. No alteration of the expression level of IFNAR-1 was observed with respect to the −408 genotypes or to interferon treatment response. These data suggest a role for the IFNAR pathway in susceptibility to MS.
PB Elsevier
YR 2005
FD 2005-04-22
LK https://hdl.handle.net/10630/32983
UL https://hdl.handle.net/10630/32983
LA eng
NO Leyva, L., Fernández, O., Fedetz, M., Blanco, E., Fernández, V. E., Oliver, B., León, A., Pinto-Medel, M.-J., Mayorga, C., Guerrero, M., Luque, G., Alcina, A., & Matesanz, F. (2005). IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. Journal of Neuroimmunology, 163(1), 165–171.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026